239 related articles for article (PubMed ID: 27256046)
1. [Value of MDM2, CDK4 and SATB2 immunohistochemistry in histologic diagnosis of low-grade osteosarcoma].
Chen CY; Zhang HZ; Jiang ZM; Zhou J; Chen J; Liu L
Zhonghua Bing Li Xue Za Zhi; 2016 Jun; 45(6):387-92. PubMed ID: 27256046
[TBL] [Abstract][Full Text] [Related]
2. MDM2 and CDK4 immunohistochemistry is a valuable tool in the differential diagnosis of low-grade osteosarcomas and other primary fibro-osseous lesions of the bone.
Dujardin F; Binh MB; Bouvier C; Gomez-Brouchet A; Larousserie F; Muret Ad; Louis-Brennetot C; Aurias A; Coindre JM; Guillou L; Pedeutour F; Duval H; Collin C; de Pinieux G
Mod Pathol; 2011 May; 24(5):624-37. PubMed ID: 21336260
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemical analysis of MDM2 and CDK4 distinguishes low-grade osteosarcoma from benign mimics.
Yoshida A; Ushiku T; Motoi T; Shibata T; Beppu Y; Fukayama M; Tsuda H
Mod Pathol; 2010 Sep; 23(9):1279-88. PubMed ID: 20601938
[TBL] [Abstract][Full Text] [Related]
4. Clinical outcome of low-grade central osteosarcoma and role of CDK4 and MDM2 immunohistochemistry as a diagnostic adjunct.
Jeon DG; Koh JS; Cho WH; Song WS; Kong CB; Cho SH; Lee SY; Lee SY
J Orthop Sci; 2015 May; 20(3):529-37. PubMed ID: 25740728
[TBL] [Abstract][Full Text] [Related]
5. Special AT-rich sequence-binding protein 2 (SATB2) expression is sensitive but may not be specific for osteosarcoma as compared with other high-grade primary bone sarcomas.
Davis JL; Horvai AE
Histopathology; 2016 Jul; 69(1):84-90. PubMed ID: 26644288
[TBL] [Abstract][Full Text] [Related]
6. The utility of SATB2 immunohistochemical expression in distinguishing between osteosarcomas and their malignant bone tumor mimickers, such as Ewing sarcomas and chondrosarcomas.
Machado I; Navarro S; Picci P; Llombart-Bosch A
Pathol Res Pract; 2016 Sep; 212(9):811-6. PubMed ID: 27465835
[TBL] [Abstract][Full Text] [Related]
7. MDM2 and CDK4 expression in periosteal osteosarcoma.
Righi A; Gambarotti M; Benini S; Gamberi G; Cocchi S; Picci P; Bertoni F
Hum Pathol; 2015 Apr; 46(4):549-53. PubMed ID: 25680902
[TBL] [Abstract][Full Text] [Related]
8. MDM2 and CDK4 immunohistochemical coexpression in high-grade osteosarcoma: correlation with a dedifferentiated subtype.
Yoshida A; Ushiku T; Motoi T; Beppu Y; Fukayama M; Tsuda H; Shibata T
Am J Surg Pathol; 2012 Mar; 36(3):423-31. PubMed ID: 22301501
[TBL] [Abstract][Full Text] [Related]
9. Parosteal osteosarcoma.
Hang JF; Chen PC
Arch Pathol Lab Med; 2014 May; 138(5):694-9. PubMed ID: 24786129
[TBL] [Abstract][Full Text] [Related]
10. The Utility of MDM2 and CDK4 Immunohistochemistry and MDM2 FISH in Craniofacial Osteosarcoma.
Limbach AL; Lingen MW; McElherne J; Mashek H; Fitzpatrick C; Hyjek E; Mostofi R; Cipriani NA
Head Neck Pathol; 2020 Dec; 14(4):889-898. PubMed ID: 32026294
[TBL] [Abstract][Full Text] [Related]
11. Giant cell rich osteosarcoma revisited-diagnostic criteria and histopathologic patterns, Ki67, CDK4, and MDM2 expression, changes in response to bisphosphonate and denosumab treatment.
Chow LT
Virchows Arch; 2016 Jun; 468(6):741-55. PubMed ID: 27003154
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemical and FISH analysis of MDM2 and CDK4 in a dedifferentiated extraskeletal osteosarcoma arising in the vastus lateralis muscle: differential diagnosis and diagnostic algorithm.
von Baer A; Ehrhardt A; Baumhoer D; Mayer-Steinacker R; Schultheiss M; Abdul-Nou T; Mentzel T; Fend F; Möller P; Jundt G; Barth TF
Pathol Res Pract; 2014 Oct; 210(10):698-703. PubMed ID: 24974983
[TBL] [Abstract][Full Text] [Related]
13. [Detection of MDM2 gene amplification by fluorescence in situ hybridization and its diagnostic value in low-grade osteosarcoma].
Li L; Zhang M; Dong RF; Su YB; Ding Y
Zhonghua Bing Li Xue Za Zhi; 2024 Mar; 53(3):237-242. PubMed ID: 38433050
[No Abstract] [Full Text] [Related]
14. Role of MDM2, CDK4, BCL2, Parafibromin and Galectin 1 in Differentiating Osteosarcoma from its Benign Fibro-osseous Lesions.
Kaur H; Kala S; Sood A; Mridha AR; Kakkar A; Yadav R; Mishra S; Mishra D
Head Neck Pathol; 2022 Sep; 16(3):728-737. PubMed ID: 35220546
[TBL] [Abstract][Full Text] [Related]
15. Sclerosing epithelioid fibrosarcoma of bone: morphological, immunophenotypical, and molecular findings of 9 cases.
Kosemehmetoglu K; Ardic F; Kilpatrick SE; Aydingoz U; Sumathi VP; Michal M
Virchows Arch; 2021 Apr; 478(4):767-777. PubMed ID: 33084978
[TBL] [Abstract][Full Text] [Related]
16. Well-differentiated liposarcoma with low-grade osteosarcomatous component: an underrecognized variant.
Yoshida A; Ushiku T; Motoi T; Shibata T; Fukayama M; Tsuda H
Am J Surg Pathol; 2010 Sep; 34(9):1361-6. PubMed ID: 20697254
[TBL] [Abstract][Full Text] [Related]
17. [Significance of SATB2 in the pathologic diagnosis of osteosarcoma].
Li M; Cai YP; Lu KY; Chen Y; Zhu X; Yin Y; Tang J
Zhonghua Bing Li Xue Za Zhi; 2016 Sep; 45(9):631-5. PubMed ID: 27646893
[TBL] [Abstract][Full Text] [Related]
18. Primary sclerosing epithelioid fibrosarcoma of bone: analysis of a series.
Wojcik JB; Bellizzi AM; Dal Cin P; Bredella MA; Fletcher CD; Hornicek FJ; Deshpande V; Hornick JL; Nielsen GP
Am J Surg Pathol; 2014 Nov; 38(11):1538-44. PubMed ID: 24921641
[TBL] [Abstract][Full Text] [Related]
19. SATB2 and MDM2 Immunoexpression and Diagnostic Role in Primary Osteosarcomas of the Jaw.
Owosho AA; Ladeji AM; Adesina OM; Adebiyi KE; Olajide MA; Okunade T; Palmer J; Kehinde T; Vos JA; Cole G; Summersgill KF
Dent J (Basel); 2021 Dec; 10(1):. PubMed ID: 35049602
[TBL] [Abstract][Full Text] [Related]
20. A new subtype of high-grade mandibular osteosarcoma with RASAL1/MDM2 amplification.
Guérin M; Thariat J; Ouali M; Bouvier C; Decouvelaere AV; Cassagnau E; Aubert S; Lepreux S; Coindre JM; Valmary-Degano S; Larousserie F; Meilleroux J; Projetti F; Stock N; Galant C; Marie B; Peyrottes I; de Pinieux G; Gomez-Brouchet A
Hum Pathol; 2016 Apr; 50():70-8. PubMed ID: 26997440
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
